Published: 6 November 2019
Author(s): Giuseppe Patti, Alessandro Sticchi, Vincenzo Pasceri
Section: Letter to the Editor

In randomized trials the use of dual antithrombotic therapy (DAT) versus single antithrombotic therapy (SAT) in patients with chronic coronary syndrome (CCS) reduced the risk of major adverse cardiovascular events [1]. However, the reduction in mortality with DAT was significant only in the COMPASS study and was inconsistent and variable across the other investigations [1]. In particular, what effect on different types of adverse events drives the survival benefit in patients receiving DAT is unclear.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.